Aberrantly expressed miR-582-3p maintains lung cancer stem cell-like traits by activating Wnt/β-catenin signalling

Nature Communications

Volumn 6, Issue , 2015, Pages

  Fang, Lishan ^a   Cai, Junchao ^a   Chen, Baixue ^a   Wu, Shanshan ^a   Li, Rong ^a   Xu, Xiaonan ^a   Yang, Yi ^a,b   Guan, Hongyu ^a   Zhu, Xun ^a   Zhang, Le ^a   Yuan, Jie ^a   Wu, Jueheng ^a   Li, Mengfeng ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL COMMUNITY; BIOTECHNOLOGY; CANCER; CELLS AND CELL COMPONENTS; DIGESTIVE SYSTEM; GENE EXPRESSION; MUTATION; PROTEIN; SURVIVAL; TUMOR;

ANIMALIA;

AXIN; AXIN2 PROTEIN, HUMAN; BETA CATENIN; DKK3 PROTEIN, HUMAN; MEMBRANE PROTEIN; MICRORNA; MIRN582 MICRORNA, HUMAN; SFRP1 PROTEIN, HUMAN; SIGNAL PEPTIDE; WNT PROTEIN;

ANIMAL; BAGG ALBINO MOUSE; CANCER STEM CELL; CHINA; EPIDEMIOLOGY; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; LUNG TUMOR; MALE; METABOLISM; MORTALITY; NON SMALL CELL LUNG CANCER; NUDE MOUSE; PHENOTYPE; PHYSIOLOGY; TUMOR CELL LINE; TUMOR RECURRENCE;

ANIMALS; AXIN PROTEIN; BETA CATENIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHINA; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, EXPERIMENTAL; NEOPLASTIC STEM CELLS; PHENOTYPE; WNT PROTEINS;

EID: 84944314349     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9640     Document Type: Article

References (57)

1. Ferlay, J. S. I. et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Accessed on 15 March 2014. International Agency for Research on Cancer, 2013; Available at: http://globocaniarcfr.
2. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA. Cancer. J. Clin. 63, 11-30 (2013).
3. Taylor, M. D. et al. Tumor recurrence after complete resection for non-small cell lung cancer. Ann. Thorac. Surg. 93, 1813-1820; discussion 1820-1811 (2012).
4. Collins, B. J., Kleeberger,W. & Ball, D. W. Notch in lung development and lung cancer. Semin. Cancer Biol. 14, 357-364 (2004).
5. Pepicelli, C. V., Lewis, P. M. & McMahon, A. P. Sonic hedgehog regulates branching morphogenesis in the mammalian lung. Curr. Biol. 8, 1083-1086 (1998).
6. Uematsu, K. et al. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene 22, 7218-7221 (2003).
7. Visvader, J. E. & Lindeman, G. J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. 8, 755-768 (2008).
8. O'Brien, C. A., Kreso, A. & Jamieson, C. H. M. Cancer stem cells and self-renewal. Clin. Cancer Res. 16, 3113-3120 (2010).
9. Heidel, F. H. et al. Genetic and pharmacologic inhibition of b-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell 10, 412-424 (2012).
10. Vermeulen, L. et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12, 468-476 (2010).
11. Malanchi, I. et al. Cutaneous cancer stem cell maintenance is dependent on b-catenin signalling. Nature 452, 650-653 (2008).
12. Clevers, H. & Nusse, R. Wnt/beta-catenin signaling and disease. Cell 149, 1192-1205 (2012).
13. Kawano, Y. & Kypta, R. Secreted antagonists of the Wnt signalling pathway. J. Cell. Sci. 116, 2627-2634 (2003).
14. Stewart, D. J. Wnt signaling pathway in non-small cell lung cancer. J. Natl Cancer Inst. 106, djt356 (2014).
15. Tseng, R. C. et al. Epigenetic silencing of AXIN2/betaTrCP and deregulation of p53-mediated control lead to wild-type beta-catenin nuclear accumulation in lung tumorigenesis. Oncogene 27, 4488-4496 (2008).
16. Fukui, T. et al. Transcriptional silencing of secreted frizzled related protein 1 (SFRP 1) by promoter hypermethylation in non-small-cell lung cancer. Oncogene 24, 6323-6327 (2005).
17. Kobayashi, K. et al. Reduced expression of the REIC/Dkk-3 gene by promoterhypermethylation in human tumor cells. Gene 282, 151-158 (2002).
18. Coscio, A. et al. Genetic variants of the Wnt signaling pathway as predictors of recurrence and survival in early-stage non-small cell lung cancer patients. Carcinogenesis 35, 1284-1291 (2014).
19. Nguyen, D. X. et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138, 51-62 (2009).
20. Sunaga, N. et al. Constitutive activation of the Wnt signaling pathway by CTNNBI (beta-catenin) mutations in a subset of human lung adenocarcinoma. Genes Chromosomes Cancer 30, 316-321 (2001).
21. Ohgaki, H. et al. APC mutations are infrequent but present in human lung cancer. Cancer Lett. 207, 197-203 (2004).
22. Garzon, R., Calin, G. A. & Croce, C. M. MicroRNAs in Cancer. Annu. Rev. Med. 60, 167-179 (2009).
23. Cai, J. et al. MicroRNA-374a activates Wnt/beta-catenin signaling to promote breast cancer metastasis. J. Clin. Invest. 123, 566-579 (2013).
24. Xia, H., Ooi, L. L. & Hui, K. M. MiR-214 targets beta-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma. PLoS ONE 7, e44206 (2012).
25. Strillacci, A. et al. Loss of miR-101 expression promotes Wnt/beta-catenin signalling pathway activation and malignancy in colon cancer cells. J. Pathol. 229, 379-389 (2013).
26. Liu, X. H. et al. MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5. BMC Cancer 12, 348 (2012).
27. Oneyama, C. et al. MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. Oncogene 30, 3489-3501 (2011).
28. Brown, B. D. et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat. Biotechnol. 25, 1457-1467 (2007).
29. Ebert, M. S., Neilson, J. R. & Sharp, P. A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 4, 721-726 (2007).
30. Ramalho-Santos, M., Yoon, S., Matsuzaki, Y., Mulligan, R. C. & Melton, D. A. "Stemness": transcriptional profiling of embryonic and adult stem cells. Science 298, 597-600 (2002).
31. Labbe, E. et al. Transcriptional cooperation between the transforming growth factor-beta and wnt pathways in mammary and intestinal tumorigenesis. Cancer Res. 67, 75-84 (2007).
32. Lee, R. H., Yoon, N., Reneau, J. C. & Prockop, D. J. Preactivation of human MSCs with TNF-alpha enhances tumor-suppressive activity. Cell Stem Cell 11, 825-835 (2012).
33. Uren, A. et al. Secreted frizzled-related protein-1 binds directly to Wingless and is a biphasic modulator of Wnt signaling. J. Biol. Chem. 275, 4374-4382 (2000).
34. Caldwell, G. M. et al. The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res. 64, 883-888 (2004).
35. Licchesi, J. D. et al. Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis 29, 895-904 (2008).
36. Nozaki, I. et al. Reduced expression of REIC/Dkk-3 gene in non-small cell lung cancer. Int. J. Oncol. 19, 117-121 (2001).
37. Hsieh, S. Y., Hsieh, P. S., Chiu, C. T. & Chen, W. Y. Dickkopf-3/REIC functions as a suppressor gene of tumor growth. Oncogene 23, 9183-9189 (2004).
38. Yue, W. et al. Downregulation of Dkk3 activates beta-catenin/TCF-4 signaling in lung cancer. Carcinogenesis 29, 84-92 (2008).
39. Veeck, J. et al. Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer. BMC Cancer 9, 217 (2009).
40. Uchino, K. et al. Therapeutic effects of microRNA-582-5p and-3p on the inhibition of bladder cancer progression. Mol. Ther. 21, 610-619 (2013).
41. Dean, M., Fojo, T. & Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer. 5, 275-284 (2005).
42. Kim, C. F. et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121, 823-835 (2005).
43. Vlashi, E. & Pajonk, F. Targeted cancer stem cell therapies start with proper identification of the target. Mol. Cancer. Res. 8, 291; author reply 291 (2010).
44. Takahashi-Yanaga, F. & Kahn, M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin. Cancer Res. 16, 3153-3162 (2010).
45. Takebe, N., Harris, P. J., Warren, R. Q. & Ivy, S. P. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat. Rev. Clin. Oncol. 8, 97-106 (2011).
46. Kahn, M. Can we safely target the WNT pathway? Nat. Rev. Drug Discov. 13, 513-532 (2014).
47. Cai, J. et al. miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer. Cancer Res. 73, 5402-5415 (2013).
48. Simon, R. et al. Analysis of gene expression data using BRB-ArrayTools. Cancer Inform. 3, 11-17 (2007).
49. Tusher, V. G., Tibshirani, R. & Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl Acad. Sci. USA 98, 5116-5121 (2001).
50. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).
51. Wang, Y., Jia, L. &Wu, C. Y. Triptolide inhibits the differentiation of Th17 cells and suppresses collagen-induced arthritis. Scand. J. Immunol. 68, 383-390 (2008).
52. Chi, W. et al. IL-23 promotes CD4(+) T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J. Allergy Clin. Immunol. 119, 1218-1224 (2007).
53. Jiang, L. et al. MicroRNA-30e∗ promotes human glioma cell invasiveness in an orthotopic xenotransplantation model by disrupting the NF-kappaB/IkappaBalpha negative feedback loop. J. Clin. Invest. 122, 33-47 (2012).
54. Wang, J. et al. Retinoic acid-inducible gene-I mediates late phase induction of TNF-alpha by lipopolysaccharide. J. Immunol. 180, 8011-8019 (2008).
55. Tan, L. P. et al. A high throughput experimental approach to identify miRNA targets in human cells. Nucleic Acids Res. 37, e137 (2009).
56. Zhang, Y. et al. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett. 303, 21-28 (2011).
57. Li, H. et al. Rapid pulmonary fibrosis induced by acute lung injury via a lipopolysaccharide three-hit regimen. Innate Immun. 15, 143-154 (2009).